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Objectives: The approved methods for sweat testing, Gibson-Cooke Pilocarpine
Iontophoresis (GCQPIT) or the Wescor Macroduct® Sweat Test system, have many
steps that can and do lead to errors. The GCQPIT method is 54 years old, was
never intended for newborns, has scared parents and burned infants. Thus, there is
a critical need to improve sweat testing technology.
Methods: The CF Quantum® Sweat Test (CFQT) System consists of:
a. a controller and electrode set that is worn on the arm for pilocarpine ionto-
phoresis;
b. a chloride test patch that collects the sample. Chloride ions in the sweat sample
come into contact with silver chromate in the test patch, and an ion exchange
reaction occurs which creates silver chloride, an insoluble white precipitate
formed in the center of the patch;
c. a CF Analyzer utilizes a camera and proprietary software that scans the reacted
chloride test patch and calculates the concentration of chloride and volume of
sweat collected.
Herein are preliminary results of a multicenter study. Patients with a previous
diagnosis of CF or referred to the sweat testing lab had bilateral GCQPIT or
Macroduct® and bilateral CFQT tests performed. Thus far, 57 subjects with a
known diagnosis of CF and 56 subjects referred to the sweat test lab have had both
tests performed. There is excellent agreement of sweat chloride values between
GCQPIT/Macroduct® and CFQT with a Pearson correlation coefﬁcient of r = 0.97.
In a post-test questionnaire, 85% of parents/patients preferred the CFQT.
Conclusion: The CFQT yields sweat chloride values that are equivalent to that of
GCQPIT/Macroduct sweat testing.
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Objectives: After a positive newborn screening test for cystic ﬁbrosis (CF) a
sweat test is performed for further diagnosis. The success rate of routine methods
(Macroduct/QPIT) in newborns is 87%. The Nanoduct, is easier to perform and
less sweat is needed.
Aim of the study was to investigate the success rate of Nanoduct in newborns
compared to Macroduct/QPIT. Exploring the optimum cut-off points.
Methods: All newborns with a positive screening test result for CF were included,
after informed consent of the parents. Macroduct/QPIT and Nanoduct were per-
formed simultaneously. Sweat production and collection were performed according
to international guidelines. Chloride concentration was determined in the laboratory
for QPIT/Macroduct. With the Nanoduct sweat was collected in a micro capillary
and the conductivity was determined.
Conclusion: Ninety newborns were included, 12 with classical CF, 6 non-classical
CF. Success rate of the Macroduct/QPIT was 91% compared to 96% for the Nan-
oduct (McNemar, p = 0.388). The success rate of the Nanoduct is comparable to the
Macroduct/QPIT. Mean difference between Cl− concentration (QPIT/Macroduct)
and conductivity (Nanoduct) was 26.6mmol/l (SD 12.2; range 21−69). The Area
under the ROC curve for conductivity was 0.998, with ideal cut-off levels 92mmol/l
and 67mmol/l.
The ideal cut-off points for the Nanoduct in our population are comparable to
former studies; positive when conductivity is above 90mmol/l and negative under
70mmol/l.
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Sweat Chloride testing (SC) has been the standard diagnostic test for CF and the last
step in all CF NBS programs to conﬁrm a diagnosis. The California NBS program
follows a unique approach which includes DNA analysis by focused sequencing
so that only infants with 2 CFTR mutations/variants are referred to CF centers for
evaluation.
Objectives: We are conducting a study of repeated SC in a cohort of infants iden-
tiﬁed by CF NBS to carry 2 CFTR mutations/variants to evaluate for longitudinal
changes.
Methods: Infants undergo SC at baseline, 1 month later and at ages 6, 12
and 24 months. Among 37 infants enrolled so far mean SC at baseline was
45.5±35mmol/L (Median 33, IQR 46). Ten (27%) had SC >60mmol/L, 10 (27%)
30−60mmol/L and 17 (45%) below 30mmol/L. By genetic analysis, 57% of the
alleles are affected by a severe mutation (class I-III), but only 27% of the infants
carried two copies of severe mutations. As expected, by CFTR genotype patients
carrying only severe mutations (classes I-III) had a higher baseline SC than patients
carrying at least one mild mutation (classes IV-V), 105.4 vs 36mmol/L. Half of
the infants have already passed their ﬁrst year of life. At 1 year of age infants with
initial SC< 60mmol/L have shown a mild but non-signiﬁcant increase in SC of
7.4mmol/L (p = 0.15). Among this group, only 1 infant showed an increase into
the diagnostic category and 1 additional infant changed category from negative to
indeterminate.
Conclusion: Sweat chloride values do not change substantially from the initial test,
even among infants with milder mutations. Longitudinal follow up of these infants
continues as well as ongoing enrollment of new patients.
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Body plethysmography is used to measure airway resistance. The airway resistance
can also be measured through the nose resulting in a nasal airway resistance (NAR).
NAR in patients with CF can be increased because of the high prevalence of
rhinosinusitis and nasal polyps.
Objective: Investigation of nasal airway resistance in adult patients with Cystic
Fibrosis.
Methods: In 104 adult patients with CF, NAR was measured using body plethys-
mography. The subject was placed in a body box with a CPAP mask covering
mouth and nose. Three measurements followed; breathing through the mouth (Raw),
breathing through the nose (Rn) and a second measurement through the nose
after administration of the decongestant xylometazoline HCl 0.1% (Rnxylo). Nasal
airway resistance was calculated by: Rn-Raw. The effect of xylometazoline was
calculated by: Rn-Rnxylo.
Results: The mean age of 104 patients was 34.8 years (range 19−63) and 52.9% was
male. Since no normal values exist for NAR, only results from within one patient
were assessed. Surprisingly, NAR had a negative value in 17 patients, indicating that
the resistance through the mouth was higher than through the nose. The NAR after
xylometazoline had a negative value in 39 patients. These results could indicate
the absence of a decongesting effect of xylometazoline. But more important, these
negative results could also indicate a limited value of body plethysmography in
measuring NAR in CF patients.
Conclusion: The results of measuring NAR in CF patients were difﬁcult to interpret.
Measuring NAR using a body plethysmograph seems to have limited value in routine
care of CF patients.
